Jiangsu Yanshen’s Swine Flu Vaccine Approved by the SFDA

Did you know?

ChinaBio^® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…

More white papers:

>>China Partnering 2012: Driving Future Innovation

>>China Life Science 2012: From Local to Global

Free Content

Week in Review

In My Opinion

Free Articles

Education Center

Interfax-BW Releases

Subscriber Content

Jiangsu Yanshen’s Swine Flu Vaccine Approved by the SFDA

publication date: Sep 22, 2009

Jiangsu Yanshen Biological Technology Stock Co. was given a new drug certificate and production license from the SFDA for the company’s H1N1 flu vaccine. The action brings the number of approved manufacturers of H1N1 vaccines in China to six. Simcere Pharmaceutical Company (先声药业) owns a 37.5% stake in Jiangsu Yanshen, which it bought in May of this year for 195.5 million RMB ($28.8 million). More details...

Stock Symbol: (NYSE: SCR)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Click here to join.